Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2015, Article ID 908708, 5 pages
http://dx.doi.org/10.1155/2015/908708
Clinical Study

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia

1Department of Hematology and Immunology, Obafemi Awolowo University, Ile-Ife 234-220005, Nigeria
2Department of Hematology and Blood Transfusion, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife 234-220005, Nigeria

Received 30 June 2015; Revised 27 August 2015; Accepted 30 August 2015

Academic Editor: Estella M. Matutes

Copyright © 2015 Anthony A. Oyekunle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Kantarjian, C. Sawyers, A. Hochhaus et al., “Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia,” The New England Journal of Medicine, vol. 346, no. 9, pp. 645–652, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. V. Melo, T. P. Hughes, and J. F. Apperley, “Chronic myeloid leukemia,” The American Society of Hematology, pp. 132–152, 2003. View at Google Scholar · View at Scopus
  3. S. Faderl, H. M. Kantarjian, and M. Talpaz, “Chronic myelogenous leukemia: update on biology and treatment,” Oncology, vol. 13, no. 2, pp. 169–180, 1999. View at Google Scholar · View at Scopus
  4. C. L. Sawyers, “Chronic myeloid leukemia,” The New England Journal of Medicine, vol. 340, no. 17, pp. 1330–1340, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. C. C. Okany and O. O. Akinyanju, “Chronic leukaemia: an African experience,” Medical Oncology and Tumor Pharmacotherapy, vol. 6, no. 3, pp. 189–194, 1989. View at Google Scholar · View at Scopus
  6. P. O. Boma, M. A. Durosinmi, I. A. Adediran, N. O. Akinola, and L. Salawu, “Clinical and prognostic features of Nigerians with chronic myeloid leukemia,” The Nigerian Postgraduate Medical Journal, vol. 13, no. 1, pp. 47–52, 2006. View at Google Scholar · View at Scopus
  7. M. A. Durosinmi, J. O. Faluyi, A. A. Oyekunle et al., “The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia,” Cellular Therapy and Transplantation, vol. 1, no. 2, pp. 58–62, 2008. View at Publisher · View at Google Scholar
  8. K. G. Koffi, D. C. Nanho, E. N'Dathz et al., “The effect of imatinib mesylate for newly diagnosed philadelphia chromosome-positive, chronic-phase myeloid leukemia in sub-saharan african patients: the experience of côte d'ivoire,” Advances in Hematology, vol. 2010, Article ID 268921, 6 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Sokal, E. B. Cox, M. Baccarani et al., “Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia,” Blood, vol. 63, no. 4, pp. 789–799, 1984. View at Google Scholar · View at Scopus
  10. J. M. Goldman, “Treatment of chronic myeloid leukaemia lessons and challenges,” International Journal of Hematology, vol. 76, supplement 2, pp. 189–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study,” Journal of Clinical Oncology, vol. 24, no. 18, supplement, abstract 6506, 2006. View at Google Scholar
  13. A. Oyekunle, E. Klyuchnikov, S. Ocheni et al., “Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid Leukemia in the era of tyrosine kinase inhibitors,” Acta Haematologica, vol. 126, no. 1, pp. 30–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Gambacorti-Passerini, L. Antolini, F.-X. Mahon et al., “Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib,” Journal of the National Cancer Institute, vol. 103, no. 7, pp. 553–561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Mendizabal, P. Garcia-Gonzalez, and P. H. Levine, “Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries,” Cancer Epidemiology, vol. 37, no. 3, pp. 247–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Hochhaus, B. Druker, C. Sawyers et al., “Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment,” Blood, vol. 111, no. 3, pp. 1039–1043, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Hanfstein, M. C. Müller, R. Hehlmann et al., “Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML),” Leukemia, vol. 26, no. 9, pp. 2096–2102, 2012. View at Publisher · View at Google Scholar
  19. H. Kantarjian, S. O'Brien, E. Jabbour et al., “Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience,” Blood, vol. 119, no. 9, pp. 1981–1987, 2012. View at Publisher · View at Google Scholar · View at Scopus